NCT05487391View on ClinicalTrials.gov

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

PHASE3RecruitingINTERVENTIONAL
Enrollment

632

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

May 22, 2029

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

QL1706 injection

QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy

DRUG

Vinorelbine Tartrate

Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles

DRUG

Paclitaxel

Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles

DRUG

Cisplatin

Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles

DRUG

Carboplatin

Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles

DRUG

Pemetrexed

Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pulmonary Hospital, Shanghai. China, Shanghai

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY